| "“MERS-CoV Infection Treated with a Combination ofLopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-BlindRandomized Trial (MIRACLE Trial)”" |
Ongoing |
Kaletra |
3 |
RC15/142/R |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital NG (Al Ahsa), Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Genaral Hospital, Medina, prince mohammad bin abdulaziz hospital (Riyadh), ohud hospital (Medina), Buraidah Central Hospital HOME - Buraydah, Aseer Central Hospital |
| A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. |
Rejected |
Everolimus + Exemestane\Everolimus\Capecitabine |
2 |
CRAD001Y2201 |
N\A |
| EXPERT, EXPosurE Registry RiociguaT in patients with pulmonary hypertension |
Ongoing |
Riociguat |
4 |
16657 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| "Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial" |
Ongoing |
(Cyklokapron) Tranexamic Acid |
3 |
ISRCTN15088122 |
King Saud Medical City (Riyadh) |
| EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients in EMEA countries. |
Ongoing |
Riociguat |
4 |
18303 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Terminated |
Finerenone |
3 |
BAY 94-8862 16244 |
King Abdulaziz University Hospital (Jeddah) |
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD) |
Terminated |
Finerenone |
3 |
BAY 94-8862 17530 |
King Abdulaziz University Hospital (Jeddah) |
| "A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2" |
Terminated |
BAY 80-6946/Copanlisib |
3 |
BAY 80-6946 / 17322 |
King Abdulaziz University Hospital (Jeddah), King Abdullah Medical City (Makkah), King Fahad Specialist Hospital (Dammam) |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) |
Ongoing |
MEDI4736+Tremelimumab |
3 |
D419AC00003 |
King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer |
Ongoing |
MEDI4736/Paclitaxel |
2 |
ESR-14-10649 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
